✦ LIBER ✦

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer

✍ Scribed by Paz-Ares, L. G.; Biesma, B.; Heigener, D.; von Pawel, J.; Eisen, T.; Bennouna, J.; Zhang, L.; Liao, M.; Sun, Y.; Gans, S.; Syrigos, K.; Le Marie, E.; Gottfried, M.; Vansteenkiste, J.; Alberola, V.; Strauss, U. P.; Montegriffo, E.; Ong, T. J.; Santoro, A.

Book ID: 115538201
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 163 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2011.39.7646

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized phase II study of recombina

A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer

✍ Xin Zhao, Kai Mei, Xiaohong Cai, Jing Chen, Jingrui Yu, Chengya Zhou, Qiu Li 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 136 KB

Randomized, Phase III Study of Gemcitabi

Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer

✍ Perol, M.; Chouaid, C.; Perol, D.; Barlesi, F.; Gervais, R.; Westeel, V.; Crequi 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 264 KB

An International, Multicenter, Randomize

An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non–Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial

✍ Cesare Gridelli; Charles Butts; Fortunato Ciardiello; Ronald Feld; Ciro Gallo; F 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 91 KB

Phase II trial with a new schedule of ge

Phase II trial with a new schedule of gemcitabine and cisplatin for the treatment of advanced non-small cell lung cancer

✍ Chacon, J.I; Andrade, J; Lopez, L; Martinez, B; Cruz, M 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Docetaxel/gemcitabine or cisplatin/gemci

Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial

✍ D. Binder; H. Schweisfurth; C. Grah; C. Schäper; B. Temmesfeld-Wollbrück; G. Sie 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 340 KB

Docetaxel versus docetaxel plus gemcitab

Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial

✍ Georgoulias, Vassilis; Androulakis, Nikolaos; Kotsakis, Athanasios; Hatzidaki, D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 239 KB